IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3175
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$865M
Victor Perlroth
Kodiak Sciences Inc. researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD) The company was formerly known as Oligasis, LLC.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$KOD Kodiak Sciences Inc. | 43 | 24 | 33 | 88 | - | - | -916.7% | -99.6% | - | - | - | - | 0.0% | 820.0x | $865M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Kodiak Sciences Inc. (KOD) receives a "Reduce" rating with a composite score of 42.6/100. It ranks #3175 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Victor Perlroth
Chief Executive Officer
Labor Force
90
24
25
24
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for KOD
Outperforming peers — winners tend to keep winning over 3-12 months
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for KOD.
View All RatingsInsufficient data for Financial Analysis
ROE proxy -916.7% (sector -2.5%)
GM N/A vs sector 43%, OM N/A vs sector 1%
Capital turnover N/A
Rev growth N/A, 8yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Kodiak Sciences Inc. receives a Reduce rating from our analysis, with a composite score of 42.6/100 and 2 out of 5 stars, ranking #3175 out of 7,333 stocks. KOD's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
Kodiak Sciences Inc. registers a weak quality score of just 24/100, indicating significant profitability challenges. The company reports a return on equity of -916.7% (sector avg: -2.5%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
With a value score of 33/100, KOD appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 65.14x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
Kodiak Sciences Inc.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -99.6% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
KOD shows strong momentum characteristics with a score of 88/100. The stock has been trending above key moving averages, indicating solid demand from institutional buyers. Revenue growth data is not currently available, while a beta of 1.81 reflects its sensitivity to broader market moves. This level of momentum typically signals sustained investor confidence and favorable near-term price action.
Kodiak Sciences Inc. registers a low stability score of 24/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 1.81 and a debt-to-equity ratio of 820.00x (sector avg: 0.2x). Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
Kodiak Sciences Inc.'s short interest score of 22/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include high market sensitivity (beta: 1.81), elevated leverage (D/E: 820.00x), small-cap liquidity risk. At $865M (small-cap), KOD carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Kodiak Sciences Inc. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3175 of 7,333 overall (57th percentile). Key comparisons include ROE of -916.7% trailing the -2.5% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While KOD currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Short Int. (22) would have the largest impact on the composite score.
ROE 36863% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 409900% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate Kodiak Sciences Inc. (KOD) as a Reduce with a composite score of 42.6/100 at a current price of $27.97. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in momentum (88th percentile) and value (33th percentile), which together account for the majority of the composite score. Offsetting weakness in quality (24th percentile) and stability (24th percentile) tempers our overall conviction. We assign a No Moat rating (14/100), Very High uncertainty, and Poor capital allocation.
Key items to watch: balance sheet deleveraging progress. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Kodiak Sciences Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 42.6/100 places it at rank #3175 in our full 7,333-stock universe. At $865M in market capitalization, Kodiak Sciences Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Momentum indicators (88th percentile) are constructive regarding the near-term price trend. Revenue growth data is unavailable, limiting our ability to confirm whether momentum is fundamentally supported.
Margin data is not available for Kodiak Sciences Inc., which limits our assessment of the company's cost structure and operating efficiency. We rely on factor-based signals to infer business quality in the absence of detailed margin data.
At a current price of $27.97, Kodiak Sciences Inc. is trading at a premium to fundamental value. Our value factor score of 33/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 65.1x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Positive momentum (88th percentile) indicates institutional accumulation and favorable technical dynamics that tend to persist in the intermediate term.
The Reduce rating (composite 42.6/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Elevated leverage (820% D/E) amplifies downside risk and limits management's financial flexibility in adverse scenarios.
Below-average quality (24th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
High beta of 1.81 means amplified losses in market selloffs — in a broad market correction, this stock would likely decline more than the index.
We assign a Very High uncertainty rating to Kodiak Sciences Inc.. The stock exhibits multiple compounding risk factors: elevated market sensitivity (beta of 1.81), significant leverage (820% debt-to-equity), below-average price stability (24th percentile). The extreme uncertainty around future cash flows makes precise valuation difficult, and the range of outcomes is exceptionally wide. Only investors with high risk tolerance and extended time horizons should consider this name.
Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 1.81); significant leverage (820% debt-to-equity); below-average price stability (24th percentile); weak quality scores (24th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 24th percentile and quality factor at the 24th percentile provide a quantitative summary of the overall risk landscape.
We identify limited risk mitigants at this time, which contributes to our very high uncertainty assessment. Investors should monitor for improvement in balance sheet metrics, margin stability, and business predictability that could warrant a downgrade in our risk assessment over time.
We rate Kodiak Sciences Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-916.7%), elevated leverage (820% D/E), weak asset returns (ROA -99.6%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Kodiak Sciences Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Kodiak Sciences Inc. receives a Reduce rating with a composite score of 42.6/100 (rank #3175 of 7,333). Our quantitative framework assigns a No Moat (14/100, trend: stable), Very High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 39/100.
Our analysis does not support a constructive view on Kodiak Sciences Inc. at this time. The combination of limited competitive advantages, very high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Kodiak Sciences Inc. a meaningful economic moat, scoring 14/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 10/20.
The strongest moat sources are margin superiority (10/20) and economic value creation (2.5/20). GM N/A vs sector 43%, OM N/A vs sector 1%. ROE proxy -916.7% (sector -2.5%). These pillars form the core of Kodiak Sciences Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include reinvestment efficiency (0/20) and growth durability (0/20). Capital turnover N/A. Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Kodiak Sciences Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers are not clearly identifiable from current fundamentals. This may reflect a company in transition, a cyclical downturn, or structural challenges in the business model. We assign a quality factor of 24/100 which further underscores our concern regarding earnings sustainability.
Return metrics include ROE of -916.7% and ROA of -99.6%. Relative to the Manufacturing sector, sector comparison data is limited, and ROE of -916.7% compares to a sector median of -2.5%.
The balance sheet reflects high leverage with D/E of 820%, which may limit financial flexibility. The sector median D/E is 0%, putting Kodiak Sciences Inc. at higher leverage than the typical peer. Elevated leverage in combination with the current margin profile warrants close monitoring for any deterioration in debt-servicing capacity.
Above 50MA
37.18%
Net New Highs
+51081
Kodiak (KOD) reports a wider-than-expected loss for fourth-quarter 2023. The company provides updates regarding its pipeline development plans.
Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth-quarter loss. Kodiak Sciences posted a quarterly loss of $1.13 per share, compared to market expectations for a loss of 77 cents per share. Kodiak Sciences shares dipped 19.9% to $5.97 on Thursday. Here are some other stocks moving in today's mid-day session. Gainers Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares jumped 430% to $25.35 after the company announced it acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio. The company also announced a private placement financing of up to $185 million. Xilio Therapeutics, Inc. (NASDAQ: XLO) gained 146% to $1.58 after the company announced an exclusive license agreement with Gilead Sciences for a tumor-activated IL-12 program. The company announced a $11.3 million private placement equity financing. Biodexa Pharmaceuticals Plc (NASDAQ: BDRX) shares climbed 80% to $1.5395. Biodexa's MTX110 showed promise in extending life expectancy against aggressive brain cancers. Ontrak, Inc. (NASDAQ: OTRK) gained 55% to $0.9239. Binah Capital Group, Inc. (NASDAQ: BCG) gained 48% to $14.05 after dipping more than 20% on Wednesday. Kidpik Corp. (NASDAQ: PIK) gained 40.7% to $4.5999. Kidpik recently regained compliance with the Nasdaq minimum bid price requirement. Allego N.V. (NASDAQ: ALLG) rose 32.8% to $1.7650. Akanda Corp. (NASDAQ: AKAN) gained 28% to $0.2053 after the company announced a plan to evaluate opportunities in Bitcoin, Blockchain and AI applications in the cannabis industry. Destiny Tech100 Inc. (NASDAQ: DXYZ) rose 26% to $22.15. REX American Resources Corporation (NYSE: REX) gained 23.2% to $54.15 following upbeat earnings. Nutriband Inc. (NASDAQ: NTRB) gained 23% to $4.98. Nutriband recently provided a clinical and regulatory path overview for its AVERSA Fentanyl patch. Summit Therapeutics Inc. (NASDAQ: ...
U.S. stocks traded mixed this morning, with the Dow Jones index trading almost flat on Thursday. Following the market opening Thursday, the Dow traded down 0.02% to 39,753.17 while the NASDAQ fell 0.08% to 16,385.80. The S&P 500 also rose, gaining, 0.04% to 5,250.38. Check This Out: Jim Cramer Likes Crown Castle, But Can't Recommend Archer Aviation: It Has 'No Earnings Power' Leading and Lagging Sectors Real estate shares jumped by 0.7% on Thursday. In trading on Thursday, information technology shares fell by 0.2%. Top Headline U.S. initial jobless claims fell by 2,000 to 210,000 in the week ending March 23, compared to market estimates of 215,000. Equities Trading UP Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares shot up 435% to $24.91 after the company announced it acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio. The company also announced a private placement financing of up to $185 million. Shares of Xilio Therapeutics, Inc. (NASDAQ: XLO) got a boost, surging 154% to $1.62 after the company announced an exclusive license agreement with Gilead Sciences for a tumor-activated IL-12 program. The company announced a $11.3 million private placement equity financing. Biodexa Pharmaceuticals Plc (NASDAQ:
Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.